Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF

IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule

Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders

Merck presents new data on cardiovascular disease at ESC Congress 2025

Merck will share two oral presentations on ASCVD treatment patterns and patient burden

Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity

The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity

WHO, ITU, and WIPO release new report on AI use in traditional medicine

The global TCIM market is expected to reach nearly US$ 600 billion by 2025

USFDA grants Priority Review for new indication of finerenone for patients with common heart failure

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

Bayer files for approval of finerenone in heart failure in Japan

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)

Biocon Biologics embarks on a three-stage strategic journey

Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries